PDF

Theranostics 2020; 10(25):11359-11375. doi:10.7150/thno.48810 This issue Cite

Research Paper

Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses

Sarah M. Cheal¹, Michael R. McDevitt^2,9, Brian H. Santich^3,4, Mitesh Patel¹, Guangbin Yang⁵, Edward K. Fung⁶, Darren R. Veach^2,9, Meghan Bell¹, Afruja Ahad¹, Daniela Burnes Vargas¹, Blesida Punzalan¹, Naga Vara Kishore Pillarsetty^2,9, Hong Xu³, Hong-fen Guo³, Sébastien Monette⁷, Adam O. Michel⁷, Alessandra Piersigilli⁷, David A. Scheinberg^1,8, Ouathek Ouerfelli⁵, Nai-Kong V. Cheung^1,3, Steven M. Larson^1,2,9

1. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
3. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
4. Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.
5. Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY.
6. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
7. Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, NY.
8. Immunology Program, Weill Cornell Medicine, New York, NY.
9. Department of Radiology, Weill Cornell Medicine, New York, NY

✉ Corresponding author: Steven M. Larson, MD, FACNM, FACR, 415 East 68th Street, Z-2064, New York, NY 10065. Tel: 646-888-2212; Fax: 212-717-3263; E-mail: larsonsorg; ORCID ID: orcid.org/0000-0002-6111-7507.

Abstract

This is the initial report of an α-based pre-targeted radioimmunotherapy (PRIT) using ²²⁵Ac and its theranostic pair, ¹¹¹In. We call our novel tumor-targeting DOTA-hapten PRIT system “proteus-DOTA” or “Pr.” Herein we report the first results of radiochemistry development, radiopharmacology, and stoichiometry of tumor antigen binding, including the role of specific activity, anti-tumor efficacy, and normal tissue toxicity with the Pr-PRIT approach (as α-DOTA-PRIT). A series of α-DOTA-PRIT therapy studies were performed in three solid human cancer xenograft models of colorectal cancer (GPA33), breast cancer (HER2), and neuroblastoma (GD2), including evaluation of chronic toxicity at ~20 weeks of select survivors.

Methods: Preliminary biodistribution experiments in SW1222 tumor-bearing mice revealed that ²²⁵Ac could not be efficiently pretargeted with current DOTA-Bn hapten utilized for ¹⁷⁷Lu or ⁹⁰Y, leading to poor tumor uptake in vivo. Therefore, we synthesized Pr consisting of an empty DOTA-chelate for ²²⁵Ac, tethered via a short polyethylene glycol linker to a lutetium-complexed DOTA for picomolar anti-DOTA chelate single-chain variable fragment (scFv) binding. Pr was radiolabeled with ²²⁵Ac and its imaging surrogate, ¹¹¹In. In vitro studies verified anti-DOTA scFv recognition of [²²⁵Ac]Pr, and in vivo biodistribution and clearance studies were performed to evaluate hapten suitability and in vivo targeting efficiency.

Results: Intravenously (i.v.) administered ²²⁵Ac- or ¹¹¹In-radiolabeled Pr in mice showed rapid renal clearance and minimal normal tissue retention. In vivo pretargeting studies show high tumor accumulation of Pr (16.71 ± 5.11 %IA/g or 13.19 ± 3.88 %IA/g at 24 h p.i. for [²²⁵Ac]Pr and [¹¹¹In]Pr, respectively) and relatively low uptake in normal tissues (all average ≤ 1.4 %IA/g at 24 h p.i.). Maximum tolerated dose (MTD) was not reached for either [²²⁵Ac]Pr alone or pretargeted [²²⁵Ac]Pr at administered activities up to 296 kBq/mouse. Single-cycle treatment consisting of α-DOTA-PRIT with either huA33-C825 bispecific anti-tumor/anti-DOTA-hapten antibody (BsAb), anti-HER2-C825 BsAb, or hu3F8-C825 BsAb for targeting GPA33, HER2, or GD2, respectively, was highly effective. In the GPA33 model, no complete responses (CRs) were observed but prolonged overall survival of treated animals was 42 d for α-DOTA-PRIT vs. 25 d for [²²⁵Ac]Pr only (P < 0.0001); for GD2, CRs (7/7, 100%) and histologic cures (4/7, 57%); and for HER2, CRs (7/19, 37%) and histologic cures (10/19, 56%) with no acute or chronic toxicity.

Conclusions: [²²⁵Ac]Pr and its imaging biomarker [¹¹¹In]Pr demonstrate optimal radiopharmacologic behavior for theranostic applications of α-DOTA-PRIT. For this initial evaluation of efficacy and toxicity, single-cycle treatment regimens were performed in all three systems. Histologic toxicity was not observed, so MTD was not observed. Prolonged overall survival, CRs, and histologic cures were observed in treated animals. In comparison to RIT with anti-tumor IgG antibodies, [²²⁵Ac]Pr has a much improved safety profile. Ultimately, these data will be used to guide clinical development of toxicity and efficacy studies of [²²⁵Ac]Pr, with the goal of delivering massive lethal doses of radiation to achieve a high probability of cure without toxicity.

Keywords: Ac-225, pretargeted radioimmunotherapy, pretargeting, radioimmunotherapy, TAT

Introduction

Pretargeted radioimmunotherapy (PRIT) combines the desirable tumor-targeting features of antibodies [1] with the ideal phamacokinetics of small-molecule radiohaptens [2] for high-therapeutic index (TI) radioimmunotherapy (RIT) [3]. PRIT has been investigated for decades as an alternative to conventional RIT with radiolabeled-IgG; popular approaches include the strept(avidin)-biotin system, bispecific anti-tumor/anti-hapten antibodies (BsAb) and radiohaptens, antibody-oligonucleotide conjugates and radiolabeled complementary oligonucleotides, and, more recently, bioorthogonal approaches (e.g., inverse-electron-demand Diels-Alder reaction and adamantane/cucurbituril system) [4-11].

Because curative therapy is a major need in solid human tumors of adults and children, we have focused our efforts on PRIT for common solid tumors, using clinically applicable antibody-based radiotargeting systems [3]. We call this development “DOTA-PRIT.” DOTA-PRIT utilizes anti-tumor antigen/anti-1,4,7,10-tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA) hapten BsAbs (IgG-single-chain variable fragment (scFv) format [12]) based on the pioneering PRIT “2D12.5” anti-metal chelate antibody for nanomolar binding to DOTA chelates of all lanthanides [13, 14]. We utilize an affinity maturated anti-DOTA antibody scFv “C825” for picomolar binding to DOTA-radiohaptens for improved in vivo radioactive bound-lifetimes of tumor-targeted radioisotopes during PRIT [15]. In this technique, the non-radioactive BsAb formulation is infused and, owing to long circulation times, it takes a couple of days to reach high a tumor-to-background ratio [12]. Once the clearing agent (CA) [16] has reduced unbound circulating anti-tumor antibody, the radiohapten in the form of radiometals carried by a DOTA-hapten [2] (molecular weight (MW) ~1 kDa) is infused and rapidly taken up by the pretargeted scFv on the BsAb. Any non-tumor-bound radiometal-DOTA complex is efficiently and rapidly cleared through the kidney, resulting in exceptionally high TI.

We have successfully applied DOTA-PRIT to a variety of solid tumor-associated antigens for high-TI targeting of β-emitting isotopes, including GD2 [17], GPA33 [18, 19], and HER2 [20] (β-DOTA-PRIT). In our hands, β-DOTA-PRIT now reliably leads to cures in animal tumors with minimal radiotoxicity. Also, for hematological cancers, β-DOTA-PRIT with ⁹⁰Y has also been shown to be curative and safe in preclinical models [21, 22].

One important limitation of DOTA-PRIT is that the methodology is confined to the β-emitting radiolanthanides, ¹⁷⁷Lu, and ⁹⁰Y, due to the hapten-binding scFv C825 antibody specificity [15]. In the present manuscript, we report a novel set of radiohaptens that permits the use of other forms of therapeutic radionuclides - in particular, α-emitters for histologic cure.

²²⁵Ac is a long-lived (t_1/2 = 9.92 d) α-particle emitter that has been extensively investigated as an ²²⁵Ac-radiolabelled anti-tumor antigen IgG (²²⁵Ac-IgG) drug platform for α-radioimmunotherapy (α-RIT; [3, 23-27]). However, for solid tumors, with the long serum half-life of IgG in blood and tissues, α-RIT with ²²⁵Ac-IgG has a limited TI, a common characteristic of large carriers with long biologic half-lives, such as IgG. In fact, ²²⁵Ac-IgG has been shown to be quite radiotoxic to kidneys of mice [28]. To resolve this problem, we reasoned that a radiohapten—with its short serum half-life and complete renal excretion, without retention—would reduce in vivo radiation exposure and be the ideal carrier for the ²²⁵Ac as part of DOTA-PRIT (α-DOTA-PRIT) [2].

We evaluated the hypothesis that a novel radiohapten precursor that we call “proteus-DOTA” (Pr) is a suitable chelator for the α-emitter ²²⁵Ac, with pharmacodynamics that mimic our “gold standard” β-radiohapten [¹⁷⁷Lu]LuDOTA-Bn. We also determined if Pr was suitable with ¹¹¹In, a radioisotope that has been used as an imaging biomarker for ²²⁵Ac-IgG [29]. We tested both the activity and toxicity of α-DOTA-PRIT in mouse xenografts of human colorectal cancer (GPA33-expressing SW1222), breast cancer (HER2-expressing BT-474), and neuroblastoma (GD2-expressing IMR-32) as models for α-therapy of human solid tumors.

Methods

Please see Supplemental Information (SI) for additional details regarding: animal models, Pr synthesis, cell culture, in vitro binding assays with [²²⁵Ac]Pr and BsAb, in vivo studies [²²⁵Ac]Pr-BsAb complex, single-photon emission computed tomography/computed tomography (SPECT/CT) image analysis, macroscopic post-mortem examination and tissue sample collection, and histopathology (microscopic evaluation).

Animal care and models

Female athymic nude mice (strain: Hsd:Athymic Nude-Foxn^1nu, Envigo, aged 6-8 weeks, average weight for six-week-old and eight-week-old animals: 18.6 and 21.0 g, respectively) were used for all experiments. The subcutaneous BT-474 tumor model [20], SW1222 tumor model [18, 19], and IMR32 or luciferase gene reporter transfected IMR32 (IMR-32/luc) tumor model [17] (~50-900 mm³ by caliper measurement, assuming ellipsoid geometry for calculation of tumor volume) was used for targeting of HER2, GPA33, or GD2 antigens, respectively, with minor modifications (described in SI). All animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center following National Institutes of Health guidelines for animal welfare.

DOTA-PRIT reagents and protocols

For all DOTA-PRIT studies, mice were given three separate intravenous (i.v.) injections: (1) 250 µg (1.19 nmol) of anti-tumor/C825 BsAb (anti-GPA33: huA33-C825 [18, 19]; anti-HER2: anti-HER2-C825 [20]; anti-GD2: hu3F8-C825 [17]) 28 h prior to radiohapten administration; and (2) CA (dextran-CA: 62.5 µg, 0.125 nmol dextran, 7.625 nmol (Y)DOTA (unless otherwise noted) or, alternatively, dendrimer-CA: 25 µg, 2.76 nmol (Y)DOTA [30]) 4 h prior to administration of (3) radiohapten (as described). Note: the dendrimer-CA was recently developed by our group as an alternative to the dextran-CA in anticipation of clinical translation, and was found to have a similar impact on in vivo pretargeting of [¹⁷⁷Lu]LuDOTA-Bn [30]. All reagents were formulated for injection in 200-250 µL normal sterile isotonic saline solution (NSS). For all injections, mice were gently warmed with a heat lamp and placed on a restrainer. Their tails were sterilized with alcohol pads, and single-bolus injections were placed into the lateral tail vein.

Biodistribution experiments

For biodistribution assay following radiotracer injection, mice were euthanized by CO₂ (g) asphyxiation and tumor and selected organs were harvested, rinsed with water and allowed to air dry, weighed, and radioassayed by gamma scintillation counting (Perkin Elmer Wallac Wizard 3”). Count rates were background- and decay-corrected, converted to activities using a system calibration factor specific for the isotope, normalized to the administered activity, and expressed as percent injected activity per gram of tissue (%IA/g). For ²²⁵Ac, each sample was counted for up to 10 min (24 h after collection when secular equilibrium was reached) using a 150 to 600 keV energy window.

Preliminary testing of DOTA-PRIT with [²²⁵Ac]DOTA-Bn

For initial pretargeting of [²²⁵Ac]DOTA-Bn, the GD2 system was used as a model. The GD2 model was used for preliminary testing of DOTA-PRIT with [²²⁵Ac]DOTA-Bn since we determined for [¹⁷⁷Lu]LuDOTA-Bn, the TI for tumor-to-blood to be highest in that model (TI = 142) [17] in comparison to HER2 (TI = 28) [20] and GPA33 (TI = 73) [19]. Ten IMR-32 tumor-bearing mice were injected with BsAb, dextran-CA (100 µg, 0.2 nmol dextran, 29 nmol of (Y)DOTA), and then an equimolar amount of either [²²⁵Ac]DOTA-Bn [31] or, for comparison, [¹⁷⁷Lu]LuDOTA-Bn [17] (1.85 MBq and 3.7 MBq of ¹⁷⁷Lu and ²²⁵Ac, respectively, 8-10 pmol; n = 5/radiohapten). Mice were sacrificed at 24 h post-injection (p.i.) of radiotracer for biodistribution assay. Note: While these different administered radioactivity doses potentially result in different anti-tumor efficacies, within 24 h post-injection we did not anticipate any effects on tumor uptake and retention of the respective radiohaptens at equimolar doses in the established tumors.

Pr synthesis

Pr consists of a three-arm DOTA radiometal-chelating agent (DO3A) separated by a tetraethylene glycol (PEG₄) linker to a ¹⁷⁵Lu (natural) lutetium complex of 2-benzyl-DOTA. Pr was synthesized by linking two bifunctional chelators: commercial 2,2',2''-(10-(17-amino-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (NH₂-PEG₄-DO3A) and non-radioactive lutetium 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA·Lu³⁺ complex) prepared from commercial p-SCN-Bn-DOTA and ¹⁷⁵LuCl₃·6 H₂O. The final product was purified using semi-preparative reverse-phase (RP) C-18 high-pressure liquid chromatography (HPLC) and characterized by liquid-chromatography/mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR).

Pr radiochemistry and assay of C825 binding of [²²⁵Ac]Pr

The ²²⁵Ac used in this research was supplied by the United States Department of Energy Office of Science by the Isotope Program in the Office of Nuclear Physics. Carrier-free ²²⁵Ac (2.146 E6 GBq/g [5.80 E4 Ci/g]) was obtained from Oak Ridge National Laboratory as a dried nitrate residue. The [²²⁵Ac]AcNO₃ was dissolved in 0.2 M Optima grade hydrochloric acid for subsequent radiochemistry. ²²⁵Ac-activity measurements were made at secular equilibrium using a CRC-15R radioisotope calibrator (Capintec, Inc.) set at 775 and multiplied the displayed activity value by 5; samples were positioned at the bottom and center of the well for measurement. No-carrier-added [¹¹¹In]InCl₃ sterile solution was obtained from Nuclear Diagnostic Products, Inc. ¹¹¹In-radioactivity measurements were made using a CRC-15R radioisotope calibrator (Capintec, Inc.) with the manufacturer's recommended settings for the isotope. Water and buffers were rendered metal-free and sterile by passing them through a column of Chelex-100 resin, followed by filtration through a sterile-filter device (0.22- or 0.45-µM). Initially, Pr was suspended in chelexed water at 10 mg/mL and immediately transferred to a 1.8-mL Nunc vial, and any unused stock was promptly stored at -20°C.

A typical synthesis of [²²⁵Ac]Pr is described, with a summary of [²²⁵Ac]Pr preparations provided in Table S1. To prepare [²²⁵Ac]Pr, 20 µL of [²²⁵Ac]AcNO₃ (2.442 MBq) in 0.2M HCl was mixed with 100 µL of 10 mg/mL Pr (1 mg; 0.74 µmoles) in a 1.8-mL Nunc vial. Next, 15 µL of L-ascorbic acid solution (150 g/L) and 100 µL of 3M NH₄OAc solution was added. The pH of the solution was verified to be ~5.5 by spotting 1 µL of the reaction mixture onto pHydrion pH paper (range, 5.0-9.0). The reaction was incubated at 60°C for 30 min, and then purified using a Sephadex C-25 column pre-equilibrated with 6 mL of NSS. The reaction mixture was added to the column and eluted with 4 mL of NSS to recover all removable activity ([²²⁵Ac]Pr; note: the % activity that washed off the resin was the % ²²⁵Ac that was complexed by Pr). The activity of [²²⁵Ac]Pr was determined to be 2.294 MBq, giving a radiochemical yield (RCY) of 94%. The final molar activity was 3108 GBq/mol. In summary, for [²²⁵Ac]Pr, the RCY ranged from 91-100% and was prepared to a final molar activity of 3.11E3-1.69E5 GBq/mol.

Using similar radiochemical methods, [¹¹¹In]Pr was prepared from [¹¹¹In]InCl₃ (153-249 MBq) and 1-150 µL of 10 mg/mL Pr (10 µg-1.5 mg; 7.42 nmol-1.11 µmol). Instead of Sephadex C-25 chromatography, the crude reaction was purified by Strata-X 33 µm polymeric RP solid phase extraction column (Phenomenex). The RCY was calculated based on the eluted product activity, and ranged from 44->98%. The final molar activity of [¹¹¹In]Pr ranged from 2.28E5-9.67E6 GBq/mol.

Radiochemical purity (RCP) of [²²⁵Ac]Pr and [¹¹¹In]Pr was evaluated by radio-HPLC using a Shimadzu Prominence HPLC system controlled by LC Solution v1.25 software and comprising an LC-20AB dual-pump module, DGU-20A3R degasser, SIL-20ACHT autosampler, SPD-20A UV-Vis detector, and Bioscan Flow-Count B-FC-1000 with PMT/NaI radioactivity detector in-line. Separations were run on an analytical 4.6 × 250 mm Gemini-NX C18 or Fusion RP C18 HPLC column (Phenomenex, Inc. Torrance, CA). HPLC conditions were as follows: solvent A - 10 mM pH 5 NH₄OAc, B - CH₃CN, 1.0 mL/min flow rate, λ = 220 nm, injection volume 5-20 µL, and gradient: 0% B to 40% B over 10 min. Samples were diluted 1:5 in 1 mM ethylenediaminetetraacetic acid (EDTA) prior to analysis. The radiochemical purity of [²²⁵Ac]Pr and [¹¹¹In]Pr was ≥91% by radio-HPLC (Figure S1).

In vitro binding assays of [²²⁵Ac]Pr were performed with anti-HER2 BsAb to evaluate C825 binding of [²²⁵Ac]Pr, followed by in vivo evaluation in BT-474 tumor-bearing mice to assay HER2 binding of the [²²⁵Ac]Pr-BsAb complex. We used the HER2 model because of the three antibody-antigen systems currently available to us for DOTA-PRIT, radiolabeled forms of trastuzumab have been studied most extensively in preclinical and clinical studies [3, 24, 32, 33].

Pr blood half-life and whole-body clearance

Five tumor-free mice were administered [¹¹¹In]Pr (740 kBq/3.38 nmol) and blood was collected via the tail vein at t = 5, 15, 30, 60, 120, and 240 min p.i. of tracer, followed by a biodistribution study at the final time point (240 min or 4 h). For comparison of the in vivo behavior of [²²⁵Ac]Pr and [¹¹¹In]Pr, groups of tumor-free mice (n = 3/tracer) were given [²²⁵Ac]Pr (1.85 kBq, 198 pmol) or [¹¹¹In]Pr (740 kBq, 200 pmol) and sacrificed 60 min p.i. for the biodistribution assay. To evaluate non-specific tumor uptake of Pr, two BT-474 tumor-bearing mice were administered [¹¹¹In]Pr (10.2 MBq and 9.50 MBq; ~300 pmol) and imaged with a dedicated small-animal SPECT/CT (NanoSPECT/CT, Bioscan, Washington, DC) at 60 min and 6 h p.i. of tracer according to previous methods [18]. In addition, serial whole-body activity measurements were collected immediately following imaging and a biodistribution assay was performed at 24 h p.i. Whole-body activity and blood activity clearance parameters were determined by fitting the data to exponential model curves using MATLAB (Mathworks, Inc.).

DOTA-PRIT with [²²⁵Ac]Pr or [¹¹¹In]Pr

For initial pretargeting of [²²⁵Ac]Pr or [¹¹¹In]Pr, the GPA33 system was used as a model. We used the GPA33 model for preliminary testing of DOTA-PRIT with radiolabeled forms of Pr since we have conducted the most in vivo experiments with this antibody-antigen system and tumor model in comparison with GD2/IMR32 and HER2/BT-474, and thus consider it to be a reliable test system for the development of novel radiohaptens. Three SW1222 tumor-bearing mice were given BsAb, dextran-CA, and [²²⁵Ac]Pr (1.85 kBq, 182 pmol) and sacrificed at 24 h p.i. for the biodistribution assay. For comparison, pretargeting of [¹¹¹In]Pr was also studied. Five SW1222 tumor-bearing mice were given BsAb, dendrimer-CA, and [¹¹¹In]Pr (n = 4, 1.67 MBq, 172 pmol or n = 1, 7.66 MBq, 790 pmol) for the biodistribution studies (all at 24 h p.i.), and SPECT/CT imaging (at 20 h p.i.), respectively.

Furthermore, biodistribution experiments were conducted at 24 h p.i. as described above with BsAb, CA, and a radiohapten ([²²⁵Ac]Pr, [¹¹¹In]Pr, and [¹⁷⁷Lu]LuDOTA-Bn) dose spanning two orders of magnitude (~170-26900 pmol) in order to determine the upper limit of tumor uptake. From the biodistribution data, a plot of tumor uptake at 24 h p.i. versus administered pmol of hapten was prepared, and nonlinear regression analysis (one site, specific binding) was performed using Prism 7 (GraphPad, Inc.) to estimate the Bmax.

Toxicity and therapy studies

An initial dose escalation toxicity study was performed with varying dose levels of [²²⁵Ac]Pr (0, 9.25, 18.5, 37, 74, 148, or 296 kBq/mouse; 910 pmol-29.1 nmol) in groups (n = 5) of tumor-free mice to determine maximum tolerated dose (MTD). This dose range was based on a previous MTD study in BALB/c mice with the PRIT reagent [²²⁵Ac]DOTA-Biotin, where lethal toxicity was observed at 110 d after treatment with 740 kBq/mouse [34]. Treated mice were monitored daily and weighed up to twice weekly for evidence of treatment-induced toxicity for 145 d (~20 w) p.i. All survivors were evaluated for radiation-induced histologic organ damage by board-certified veterinary pathologists.

All α-DOTA-PRIT studies were performed with single-cycle treatment regimens. Immediately prior to the start of treatment, tumor-bearing mice were randomized into treatment groups based on tumor volume in order to create groups with approximately equal average tumor volumes. Weight loss of 20% or a tumor diameter exceeding 10 mm (BT-474 or IMR-32/luc) or 15 mm (SW1222) was set as an endpoint. For BT-474 and IMR-32/luc, histological analysis of the site of tumor inoculation was carried out in survivors at study endpoints (for BT-474: ~130 d post-treatment; for IMR-32/luc: ~125 d post-treatment); for SW1222, no survivors were analyzed at study endpoint (~60 d post-inoculation/47 d post-treatment), as all (n = 6) had significant tumor that was apparently progressing (tumor volumes: 434 mm³, 683 mm³, 1023 mm³, 1122 mm³, 1172 mm³, and 1227 mm³). In order to establish benchmarks for toxicity and efficacy, 296 kBq (26.9 nmol) activity of pretargeted [²²⁵Ac]Pr or [²²⁵Ac]Pr alone (i.e., without BsAb and CA injections) was injected in groups of SW1222 tumor-bearing mice (n = 5-13) or groups of BT-474 tumor-bearing mice (n = 10-19). In addition, BT-474 tumor-bearing mice (n = 5) were treated with BsAb only to control for anti-tumor effects of the anti-HER2 portion of the BsAb [20]. Note: we previously demonstrated that the anti-GPA33 BsAb [19] and anti-GD2 BsAb [17] are ineffective to control tumor growth in those respective models; therefore, those treatment controls were omitted during this study. For treatment of IMR-32, 37 kBq (2.2 nmol or 2.4 nmol) activity pretargeted [²²⁵Ac]Pr or [²²⁵Ac]Pr alone injected in groups (n = 6-7) of IMR-32/luc tumor-bearing mice. A lower administered activity of [²²⁵Ac]Pr was used during this treatment study since these xenografted mouse tumors were shown to be most radiosensitive during GD2 β-DOTA-PRIT compared to the SW1222- and BT-474-tumor models [17], although we note that the relative biologic effectiveness (RBE) of radiation of different linear energy transfers (LETs) (i.e., treatment with ²²⁵Ac versus ¹⁷⁷Lu) likely varies among the different tumor models. At 110-130 d post-tumor inoculation/68-88 d post-treatment, the presence of viable IMR-32/luc cells at the site of xenograft inoculation was recorded by measuring luciferase activity using bioluminescence imaging (BLI) as described previously [17].

Hematologic toxicity and chronic tissue histopathology

For hematology of select therapy studies, blood was collected via retroorbital blood draws in tubes containing EDTA just prior to treatment start, as well as at weekly intervals up to 5 w (n = 4-5 mice/point). Automated analysis was performed on a Drew Scientific HemaVet 950FS (blood parameters analyzed: white blood cell (WBC), neutrophils (NE)#, NE%, lymphocytes (LY)#, LY%, monocytes (MO)#, MO%, eosinophils (EO)#, EO%, basophils (BA)#, BA%, red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), platelets (PLT), and mean platelet volume (MPV)). To examine chronic toxicity, a total of 19 mice were examined from the HER2 α-DOTA-PRIT and GD2 α-DOTA-PRIT therapy studies. From the HER2 α-DOTA-PRIT study, 10 mice were evaluated at 150 d p.i. of either: anti-HER2 α-DOTA-PRIT (296 kBq) (n = 6) or control treatments (n = 4; consisting of: no treatment, injection of BsAb only, or injection of [²²⁵Ac]Pr (296 kBq) only). From the GD2 α-DOTA-PRIT study, a total of 9 mice were evaluated at 141-241 d p.i. of either: anti-GD2 α-DOTA-PRIT (37 kBq) (n = 4) or tumor-free age-matched littermate controls (n = 5).

Statistical analysis

Differences in tissue uptake between cohorts were statistically analyzed with the student t test for unpaired data using Excel. Two-sided significance levels were calculated and a P value of <0.05 was considered statistically significant. Survival analysis was performed using Prism 7 (GraphPad, Inc.). Kaplan-Meier survival curves were analyzed with Mantel-Cox test. Data is presented as mean and standard deviation (SD).

Results

Preliminary DOTA-PRIT with [²²⁵Ac]DOTA-Bn, Pr synthesis and radiochemistry, and verification of C825 recognition of Pr

As shown in Figure 1A (also see Table S2), initial efforts to pretarget [²²⁵Ac]DOTA-Bn in IMR-32 tumor-bearing mice led to very low tumor uptake at 24 h p.i. in comparison with [¹⁷⁷Lu]LuDOTA-Bn at 24 h p.i. (for [²²⁵Ac]DOTA-Bn and [¹⁷⁷Lu]LuDOTA-Bn, respectively: 0.49 ± 0.28 %IA/g vs. 10.30 ± 6.42 %IA/g; P = 0.0054), prompting the development of Pr. C825 has been shown to have metal specificity [15]; e.g., with picomolar binding for DOTA complexes of Lutetium and Yttrium and nanomolar affinity for Indium and Gallium chelates, leading to significant differences in tumor uptake of corresponding radiohapten during in vivo pretargeting [16]. Therefore, we concluded that the C825 binding of [²²⁵Ac]DOTA-Bn was unsuitable for efficient in vivo α-DOTA-PRIT (Figure 1B).

The chemical synthesis route of Pr is described in Figure 1C. Pr was prepared in very high purity (>98%) and with an overall yield of 34% (please see SI for LC/MS and NMR data). Furthermore, Pr was successfully radiolabeled with ²²⁵Ac or ¹¹¹In, suggesting that the ¹⁷⁵Lu-DOTA-benzene moiety of Pr does not interfere with efficient ²²⁵Ac- or ¹¹¹In-radiometal complexation by the DO3A.

In vitro binding experiments with tracer [²²⁵Ac]Pr and excess BsAb confirmed efficient and stable scFv C825-mediated binding of [²²⁵Ac]Pr (Figure S2). Efficient tumor targeting in vivo was demonstrated using pre-formed BsAb complexed with [²²⁵Ac]Pr, suggesting that radiolabeled forms of Pr did not interfere with the BsAb anti-tumor antibody domain-tumor antigen interaction (Figure S3).

In vivo studies with radiolabeled Pr

In tumor-free mice, the blood half-life of [¹¹¹In]Pr was 7.09 min (fast; 86%) and 24.4 min (slow; 14%) (R² = 0.99) (Figure 2A), consistent with [¹⁷⁷Lu]LuDOTA-Bn (0.60 min (fast; 92%) and 24.8 min (slow; 8%)) [2]. Radiolabeled Pr tracers showed low normal tissue uptake, with the kidney having the highest activity concentration of 1 %IA/g by 1 h p.i. (Figure 2B; see also Table S3). The blood and kidney uptake of [²²⁵Ac]Pr was 0.31 ± 0.54 %IA/g and 0.63 ± 0.41 %IA/g at 1 h p.i., respectively, consistent with rapid renal clearance and negligible normal tissue uptake. After tissue dissection at 4 h p.i. of [¹¹¹In]Pr, the remaining activity in the carcass was 0.95 ± 0.16 % injected activity (%IA) (note: data not collected for [²²⁵Ac]Pr).

As revealed in the SPECT/CT images (Figure 2C), in the absence of specific tumor binding of the [¹¹¹In]Pr to pretargeted BsAb, Pr traffics quickly and almost exclusively out of the body by renal clearance. The whole-body activity assays demonstrate rapid excretion of activity with ~90-94% removal by 6 h p.i. of tracer (whole-body clearance half-lives for mouse 1 and mouse 2: 2.71 h (R² = 0.912) and 2.03 h (R² = 0.992), respectively; Figure S4A). Therefore, the whole-body clearance of [¹¹¹In]Pr is similar to that reported for [¹⁷⁷Lu]LuDOTA-Bn, as the %IA remaining of [¹⁷⁷Lu]LuDOTA-Bn in the carcass was reported to be approximately 2-4% at 4 h and 1-3% at 24 h [2]. Image-derived volume-of-interest (VOI) analysis of tumor and select normal tissues also confirmed renal clearance and minimal normal tissue uptake and retention (Figures S4B and S4C).

In vivo studies of SW1222 tumor-antigen pretargeted [²²⁵Ac]Pr or [¹¹¹In]Pr

The blood, SW1222-tumor, and kidney uptakes of pretargeted [²²⁵Ac]Pr at 24 h p.i. were 0.94 ± 0.37 %IA/g, 16.71 ± 5.11 %IA/g, and 1.08 ± 0.95 %IA/g, respectively, corresponding to tumor-to-organ activity ratios (T:NT) of about 18:1 and 16:1 for blood and kidney, respectively (Figure 3A and Table S4). The lowest T:NT was observed for liver (~12:1), with liver uptake of 1.40 ± 1.42 %IA/g). For [¹¹¹In]Pr, the blood, tumor, and kidney uptakes at 24 h p.i. were 0.76 ± 0.38 %IA/g, 13.19 ± 3.88 %IA/g, and 1.02 ± 0.38 %IA/g, respectively, corresponding to T:NT of approximately 17:1 and 13:1 for blood and kidney, respectively.

No major differences in the biodistribution profiles were seen between pretargeted [²²⁵Ac]Pr or [¹¹¹In]Pr with two exceptions (Table S5): liver, which on average was about three times higher for [²²⁵Ac]Pr (1.40 ± 1.42 %IA/g versus 0.47 ± 0.20 %IA/g for [²²⁵Ac]Pr or [¹¹¹In]Pr, respectively; P = 0.066, not significant), and bone, which was higher for [¹¹¹In]Pr (not detectable above background versus 0.16 ± 0.06 %IA/g for [²²⁵Ac]Pr or [¹¹¹In]Pr, respectively). We found no evidence of hepatic damage, however, on immunohistochemistry (IHC) of mice injected with [²²⁵Ac]Pr (Tables S6 and S11). Biodistribution analysis at 24 h p.i. following in vivo competition studies showed maximum tumor uptake (“Bmax”) of ~60 pmol radiohapten per gram of SW1222 tumor ((Bmax = 62.23, R² = 0.88; Figure 3B), as well as verified that pretargeting of Pr to tumor is similar to [¹⁷⁷Lu]LuDOTA-Bn. These data will serve as a guide for therapeutic dosing of radiolabeled forms of Pr, as maximizing the relative uptake of tumor to normal tissues is essential for high-TI targeting.

 Figure 1 

Preliminary in vivo pretargeting studies with [²²⁵Ac]DOTA-Bn and synthesis of Pr. A. As revealed by biodistribution studies in IMR32 tumor-bearing mice (n = 5/tracer), initial efforts to use [²²⁵Ac]DOTA-Bn for GD2 α-DOTA-PRIT were unsuccessful, leading to low tumor uptake at 24 h p.i. Data is presented as mean ± SD. B. Our preliminary in vivo pretargeting studies with [²²⁵Ac]DOTA-Bn indicate that the C825 scFv of the anti-tumor/anti-DOTA BsAb does not bind [²²⁵Ac]DOTA-Bn (green radioactive circle) with ultra-high affinity, but does bind [¹⁷⁷Lu]LuDOTA-Bn (yellow radioactive circle). C. Schematic of synthesis of proteus-DOTA (Pr), precursor to the radioligands [²²⁵Ac]Pr (therapy) and [¹¹¹In]Pr (diagnosis). Initially, p-SCN-Bn-DOTA is loaded with non-radioactive Lutetium to yield p-SCN-Bn-DOTA· Lu³⁺ complex, which is then coupled with NH₂-PEG-4-DOTA under basic conditions to yield proteus-DOTA (Pr) following purification by RP C-18 HPLC. The ¹⁷⁵Lu-DOTA-benzene portion of the molecule (yellow circle) is recognized with picomolar affinity by the anti-DOTA C825 scFv domains of the DOTA-PRIT BsAb. The DO3A (green triangle) can be efficiently loaded with ²²⁵Ac or ¹¹¹In.

 Figure 2 

Pr blood half-life and whole-body clearance. A. Blood kinetics of [¹¹¹In]Pr in tumor-free athymic nude mice (n = 5) and B. biodistribution at 240 min (4 h) p.i. (n = 5). Data is presented as mean ± SD. The blood half-life of [¹¹¹In]Pr was 7.09 min (fast; 86%) and 24.4 min (slow; 14%) (R² = 0.99). Blood clearance parameters were determined by fitting the data to exponential model curves using MATLAB (Mathworks, Inc). C. Biodistribution of either [²²⁵Ac]Pr or [¹¹¹In]Pr in tumor-free athymic nude mice at 1 h p.i. (n = 3/tracer). Data is presented as mean ± SD. D. SPECT/CT images obtained at 1 h p.i. (Left: coronal slice through kidney, SPECT scale units: kBq/mL; Right: maximum-intensity projection) confirm renal clearance and minimal normal tissue uptake and retention.

Finally, highly efficient tumor pretargeting of [¹¹¹In]Pr was also verified by non-invasive SPECT/CT imaging, as SW1222-tumor can be clearly delineated in the flank at 20 h p.i. (Figure 3C). Image-based VOI (mean) analysis of tumor, kidney (left), heart, and liver revealed activity concentrations of 6.89 ± 4.68 %IA/g, 0.46 ± 0.47 %IA/g, 0.20 ± 0.24 %IA/g, and 0.22 ± 0.27 %IA/g, respectively. In addition, the average activity concentration for the highest 10% of voxels in each VOI were also tabulated; for tumor: 18.48 ± 2.92 %IA/g; kidney (left): 1.80 ± 0.79 %IA/g; heart: 0.91 ± 0.46 %IA/g; and liver 1.03 ± 0.48 %IA/g.

Therapy with α-DOTA-PRIT

Single-cycle therapy was performed in the three tumor xenograft models for initial testing of efficacy and safety. There were no significant differences in tumor volumes at time of treatment initiation between treatment groups and [²²⁵Ac]Pr alone controls. Briefly, for SW1222: [²²⁵Ac]Pr alone (n = 5; 176 ± 24 mm³, range: 136-200 mm³) versus GPA33 α-DOTA-PRIT therapy (n = 13; 171 ± 32 mm³, range: 144-248 mm³), P = 0.375; for BT-474: [²²⁵Ac]Pr alone (n = 5; 108 ± 57 mm³, range: 66-208 mm³) versus HER2 α-DOTA-PRIT therapy (n = 19; 98 ± 39 mm³, range: 49-212 mm³), P = 0.322; for IMR32/luc: [²²⁵Ac]Pr alone (n = 6; 234 ± 176 mm³, range: 69-480 mm³) versus GD2 α-DOTA-PRIT therapy (n = 7; 319 ± 278 mm³, range: 31-666 mm³), P = 0.266. Also, for BT-474, an additional control was included (treatment with BsAb only), and the tumors were significantly smaller (for BsAb only: n = 5; 63 ± 14 mm³, range: 40-74 mm³ versus HER2 α-DOTA-PRIT therapy (n = 19; 98 ± 39 mm³, range: 49-212 mm³), P = 0.032. In SW1222 tumor-bearing animals (tumor volumes at treatment start: 141-248 mm³), GPA33 α-DOTA-PRIT significantly slowed tumor progression and extended survival compared with mice treated with [²²⁵Ac]Pr only (Figure 4A and 4B). Median survival (MS; in d post-treatment) was 42 d vs. 25 d for GPA33 α-DOTA-PRIT and [²²⁵Ac]Pr only, respectively (P < 0.0001). In BT-474 tumor-bearing animals (tumor volumes at treatment start: 40-212 mm³), HER2 α-DOTA-PRIT led to 7/19 (37%) complete response (CR) and significantly extended survival compared with mice treated with controls (Figure 4C and 4D). Furthermore, 3/19 HER2 α-DOTA-PRIT treated mice died within 150 d post-treatment with tumor volumes of 141 mm³ (day 97), 67 mm³ (day 97), and no tumor (CR; died on day 140, not assessable by pathology). The remaining 16 mice (6 with CR, others with palpable mass) had pathologic examinations of tumor at study endpoint and 6/6 CRs were confirmed to be tumor-free (i.e., histologic cure). Of the 10 mice with palpable mass at site of tumor inoculation, 4/10 were histologic cures, 4/10 had small nests of neoplastic cells but no tumor, and 2/10 had residual tumor. In summary, of 16/19 assessable mice: 10/16 were cured; 4/16 had small nests; and 2/16 had residual tumor. MS (in d after treatment start) was >130 d for HER2 α-DOTA-PRIT vs. 62 d or 77 d for [²²⁵Ac]Pr or BsAb only, respectively (P < 0.0001). Notably, MS was not significantly different for treatment with [²²⁵Ac]Pr versus treatment with BsAb only (P = 0.2501). IMR-32/luc tumor-bearing animals (tumor volumes at treatment start: 31-605 mm³) treated with GD2 α-DOTA-PRIT led to 100% CR within ~30 d of treatment start with eventual tumor escape in 3/7 treated mice, while treatment with [²²⁵Ac]Pr was ineffective, with 100% of mice requiring sacrifice due to tumor progression ~30 d of treatment (Figure 4E). We observed BLI-positive (tumor volumes: 74 mm³ and 474 mm³) in 2/7 animals within 90 d of treatment (Figure S5). Of these two BLI-positive mice, one required sacrifice due to tumor burden at 117 d after treatment, and the other was sacrificed for further analysis after the tumor failed to grow above 100 mm³ within 210 d of treatment. We have observed this rare apparent spontaneous tumor regression previously during treatment studies of SW1222 with β-DOTA-PRIT (¹⁷⁷Lu) [19], and we are currently investigating the possibility of a senescent phenotype. A third mouse developed a recurrence and had to be sacrificed 133 d after treatment due to tumor burden. The remaining four mice were confirmed to be histologic cures 141-241 d after treatment. In summary, of 4/7 assessable mice: 4/4 were cured. Survival of mice treated with GD2 α-DOTA-PRIT compared with controls was significantly extended (Figure 4F); the MS (in d after treatment start) was significantly different (i.e., >125 d) for GD2 α-DOTA-PRIT, compared to 18.5 d post-treatment for [²²⁵Ac]Pr-only treatment controls (P = 0.0002).

Toxicity of [²²⁵Ac]Pr and α-DOTA-PRIT

Prior studies with long circulating ²²⁵Ac-IgG provide a valuable benchmark for toxicity comparisons to the target organ (kidney) for ²²⁵Ac toxicity after parenteral injection in mice [28]. For example, radiation nephropathy was observed in ²²⁵Ac-IgG (720 kBq/kg (12.95 kBq))-treated mice examined at 20 w (from [28], summarized in Table 1). In contrast, in our study, no acute toxicity (as weight loss >10% of baseline; Figure 5A), nor any radiation-induced histologic organ damage was observed at any [²²⁵Ac]Pr dose level at necropsy performed at 145 d (Table 1 and Table S6). Additional details are provided in SI.

Treatment studies with either: GPA33 α-DOTA-PRIT, GD2 α-DOTA-PRIT, or [²²⁵Ac]Pr only was well tolerated, with no unscheduled mortalities. Treatment with HER2 α-DOTA-PRIT was also well tolerated, but three unscheduled mortalities were noted (3/19, 16%; two mice at 97 d and a single mouse at 140 d after treatment), which may be related to estrogen supplementation in the BT-474 mouse model, which was observed during HER2 β-DOTA-PRIT [20]). No weight losses were recorded in any of the treatment groups (SW1222: Figure S7; BT-474: Figure 5B; IMR-32/luc: Figure S8). Complete blood count (CBC) measurements in the mice treated with GPA33 α-DOTA-PRIT (Figure S9) or HER2 α-DOTA-PRIT (Figure 5C) revealed no significant changes during the observation period (up to 36 d post-treatment), with the exception of WBC for HER2 α-DOTA-PRIT, which showed an average ~55% difference at 21 d post-treatment (3.82 K/uL versus 2.21 K/uL for -2 d and 21 d post-treatment, respectively; P = 0.00813), with rebound to average 2.97 K/uL at 36 d (~25% difference from -2 d post-treatment, P = 0.04488).

 Figure 3 

In vivo studies of tumor-antigen pretargeted [²²⁵Ac]Pr or [¹¹¹In]Pr. A. Comparison of biodistribution of tracer pretargeted [²²⁵Ac]Pr (n = 3) or [¹¹¹In]Pr (n = 4) in groups of SW1222 tumor-bearing mice at 24 h p.i. Data is presented as mean ± SD. B. Absolute SW1222-tumor uptake of pretargeted radiolabeled DOTA haptens determined using ex vivo biodistribution at 24 h p.i., plotted as a function of administered moles of hapten-tracer; Bmax = ~60 pmol radiohapten per gram of SW1222 tumor (R² = 0.88). The Bmax was calculated by fitting the data by nonlinear regression analysis (one site, specific binding) using Prism 7 (GraphPad, Inc.). For all data points n = 2-4 with the exception of [¹¹¹In]Pr 790 pmol, which is n = 1. Data is presented as mean ± SD. Since C825 does not bind DOTA-Bn, the molar activity of [¹⁷⁷Lu]LuDOTA-Bn (~5.45E-3 pmol/kBq or ~0.2 pmol/µCi) was calculated based on the specific activity of the as-received radionuclide (~1,110 GBq/mg or ~30 Ci/mg). On the other hand, since C825 does recognize Pr, the molar activity of [²²⁵Ac]Pr or [¹¹¹In]Pr is calculated based on the moles of added precursor during radiosynthesis as described herein. C. SPECT/CT images approximately 24 h p.i. of pretargeted [¹¹¹In]Pr (790 pmol/7.67 MBq) in a SW1222 tumor-bearing mouse (Left: coronal slice through tumor, SPECT scale units: kBq/mL; Right: maximum-intensity projection). The SW1222-tumor can be clearly delineated in the flank.

In groups treated with HER2 α-DOTA-PRIT (296 kBq), no changes in gross organ weights, apart from a moderate decrease in kidney weights (Figure S6B), nor radiation-induced histologic organ damage was observed at necropsy performed at 150 d (Figure 6 and Table S11). There was evidence of minimal to mild renal tubular injury and such changes may be observed spontaneously in aging mice, so we cannot definitively attribute this finding to treatment, although the group difference suggests a possible association with treatment. Remarkable tubuleinterstitial features included minimal to mild multifocal cortical tubular degeneration and atrophy in 5/6 (83%) treated animals. Tubulointerstitial features were all <5% (Table 1). The CBC showed no significant group differences or deviation from reference ranges (Tables S12-14). A single significant effect on serum chemistry (Table S15) that could be attributed to treatment consisted of evidence of mild elevation of serum blood urea nitrogen (BUN) and creatinine (CREA) in the mice showing minimal to mild renal tubular injury. BUN was occasionally slightly higher than the reference range while the CREA was always within the reference ranges despite the slight increase compared to untreated mice.

Histopathology analysis of the survivors from the GD2 α-DOTA-PRIT (37 kBq) study at 141-241 d revealed no treatment-related findings (Table S16). The hematology and clinical chemistry values were also within normal reference limits (Tables S17-S19). The elevated aspartate transaminase in a single treated mouse had no histopathologic correlate and was considered incidental (Mouse #4; Table S19).

Discussion

α-radiation is potentially one of the most highly focused and radiotoxic anti-cancer agents known, wherein a few radioactive atoms can kill a cancer cell. α-particles have much greater compared to β-radiation, due to their high energy deposition (α-particles: 5-8 MeV; β-particles: 0.1-1 MeV) and far shorter penetration depth (α-particles: 50-80 µm, corresponding to 2-4 typical cell diameters; β-particles: 2-12 mm) [35]. Thus, α-emitters offer high-LET radiation with multiple lethal radiation events, potentially leading to a significant number of double DNA strand breaks. In addition, high selectivity is achieved once they are cancer cell-bound, which results in minimal collateral damage to normal tissue [35].

 Figure 4 

Single-cycle therapeutic efficacy of GPA33 α-DOTA-PRIT in SW1222 tumor-bearing mice (n = 5-13), GD2 α-DOTA-PRIT in IMR-32 tumor-bearing mice (n = 6-7), and HER2 α-DOTA-PRIT in BT-474 tumor-bearing mice (n = 5-19). Tumor volumes represent mean ± SD. A. Mean SW1222 tumor volumes in mice that received GPA33 α-DOTA-PRIT (296 kBq) in comparison to [²²⁵Ac]Pr alone (296 kBq) (n = 13 and n = 5, respectively). B. Survival analysis for GPA33 α-DOTA-PRIT. MS (in d post-treatment) was 42 d vs. 25 d for GPA33 α-DOTA-PRIT and [²²⁵Ac]Pr only, respectively (P < 0.0001). C. Mean BT-474 tumor volumes in mice that received HER2 α-DOTA-PRIT (296 kBq) in comparison to [²²⁵Ac]Pr alone (296 kBq) or BsAb alone (n = 19, n = 5, and n = 5, respectively). D. Survival analysis for HER2 α-DOTA-PRIT. MS (in d after treatment start) was >130 d for HER2 α-DOTA-PRIT vs. 62 d or 77 d for [²²⁵Ac]Pr or BsAb only, respectively (P < 0.0001). E. Mean IMR-32 tumor volumes in mice that received anti-GD2 α-DOTA-PRIT (37 kBq) in comparison to [²²⁵Ac]Pr alone (37 kBq) (n = 7 and n = 6, respectively). F. Survival analysis for GD2 α-DOTA-PRIT. MS (in d after treatment start) was significantly different (i.e., >125 d) for GD2 α-DOTA-PRIT, compared to 18.5 d post-treatment for [²²⁵Ac]Pr-only treatment controls (P = 0.0002).

 Figure 5 

Toxicity evaluation after treatment with [²²⁵Ac]Pr (up to 296 kBq) or HER2 α-DOTA-PRIT (296 kBq). A. Body weight progression of groups of healthy nude mice treated with [²²⁵Ac]Pr (n = 5/dose). The MTD was not reached. Treated animal weights plotted as the percentage of pre-treatment baseline weight. The asterisk (*) indicates that the mouse required euthanasia or was discovered deceased (3/35, 9%). Data represent mean ± SD. B. Body weight progression of groups from HER2 α-DOTA-PRIT (296 kBq) study. BT-474 tumor-bearing female athymic nude mice were treated with HER2 α-DOTA-PRIT (296 kBq) or controls ([²²⁵Ac]Pr only or BsAb only) and evaluated for toxicity. Data represent mean ± SD. For [²²⁵Ac]Pr only, n = 5; for BsAb only n = 5; and for HER2 α-DOTA-PRIT, n = 19. Treated animal weights are plotted as the percentage of pre-treatment baseline weight. For clarity, data is shown until MS (62 d or 77 d for HER2 α-DOTA-PRIT and [²²⁵Ac]Pr or BsAb only, respectively). The asterisk (*) indicates that the mouse required euthanasia due to tumor burden (controls) or apparent toxicity (HER2 α-DOTA-PRIT). C. Select hematology data from groups of BT474-tumored mice undergoing treatment with HER2 α-DOTA-PRIT (296 kBq) (red line) or no treatment control (black line); n = 4 for baseline at -2 days and n = 5 for all other data. Data represent mean ± SD. WBC, white blood cells; RBC, red blood cells; PLT, platelets; HBG, hemoglobin; HCT, hematocrit.

α-RIT with whole IgG combines highly cytotoxic α radiation with efficient tumor targeting. However, the combination of slow tumor uptake and whole-body clearance creates off-target radiotoxicities. ²²⁵Ac decay results in 4 α-particles, each of which are associated with daughter radionuclides, which can be redistributed throughout the body via the circulation. Radiation nephropathy was reported in mice at administered activities of [²²⁵Ac]-IgG, ranging from 12.95-14.80 kBq/mouse [28, 36, 37]; 37 kBq/mouse was 100% lethal [38]. As an alternative to IgG with long biologic half-lives, small-size carriers with short serum half-lives such as peptides should theoretically shorten radiation exposure, but the renal uptake of such peptides can lead to significant whole-body retention of 10-30% injected dose [2], accompanied by minor (e.g., negligible protein cases observed histologically) to major kidney damage (e.g, pathologic changes consistent with radiation-induced tubular necrosis observed) based on the administered ²²⁵Ac-activity [39-41].

 Figure 6 

Representative histology of bone marrow and kidney of BT-474 tumor-bearing female athymic nude mice treated with HER2 α-DOTA-PRIT (296 kBq) or no treatment control at 150 d. A. H&E staining of bone marrow. The bone marrow in the images is from sternum (but we examined bone marrow in sternum, femur, tibia, and vertebrae in all mice and all sites were normal). Representative hematopoietic cells have been labeled with arrows. There is no difference in cellularity (i.e. cell density) of hematopoietic cells. Scale bar = 20 µm. B. H&E staining of kidney. Lesions are labeled in red on the low magnification image. Histopathology of the kidneys revealed multifocal minimal to mild chronic tubular injury in treated mice, while the kidneys of the untreated animal was histologically normal. While these lesions were interpreted as probably caused by the treatment, they were not considered adverse, as they did not appear to significantly affect renal function or general health of the animals, based on the low percentage of the renal parenchyma affected (< 5%), normal serum CREA concentration and minimal elevation of BUN, and absence of clinical signs or change in body weight. Scale bars = 1000 µm (low magnification) and 50 µm (high magnification).

Previous manifestations of PRIT were investigated clinically with objective tumor response including CRs (e.g., strept(avidin)-biotin PRIT with Yttrium-90 for treatment of non-Hodgkin's lymphoma [42]), and proof of principle for targeting human tumors in patients was achieved. Actually, for a single dose, very good targeting was achieved to tumors at doses of antibody and radioactivity, which were in a practical range. Nonetheless, using these reagents, full success including cures was essentially out of reach due to a combination of the immunogenicity of strept(avidin), the complexity of dosing schedules, and TI, including renal dose due to retention of strept(avidin). It was clear at that time that achieving radiation doses necessary to effectively treat solid tumors would be associated with intolerable toxicity, especially to kidneys. Fundamental improvement in reagents for PRIT, such as ultra-high affinity multivalent BsAb-based approaches to PRIT, including DOTA-PRIT [12, 15], generated new enthusiasm for translation due to the potential for reduced immunogenicity via use of humanized BsAb and absence of endogenous biotin interference, as well as superior TI and efficacy to prior versions of PRIT [21, 43].

α-DOTA-PRIT offers a potential solution: an anti-tumor antibody-based drug platform that harnesses radiohapten capture and glomerular filtration to significantly enhance therapeutic window and safety, possibly allowing dose escalation to cure for human tumors. Thus, we reasoned that this Pr chelator cage, with a MW of ~1.5 kDa (as [²²⁵Ac]Pr or [¹¹¹In]Pr for pretargeting ²²⁵Ac or ¹¹¹In, respectively), would have suitable uptake in tumor and clearances ideal for high-TI DOTA-PRIT. Furthermore, this Pr approach should, in principle, allow for highly efficient and specific α-particle RIT, irrespective of the tumor antigen or tumor type, a true “plug-and-play” platform.

In the current publication, we show that at radionuclide doses up to 296 kBq [²²⁵Ac]Pr per animal, or 23 times the administered activity of [²²⁵Ac]-IgG observed to be radiotoxic to kidney, there is no detectable toxicity at 140 d after injection. MTD is not reached for [²²⁵Ac]Pr and, in fact, there is no detectable histologic evidence of adverse radiation effects. Using anti-GPA33 DOTA-PRIT as a model system, we showed that [²²⁵Ac]Pr or [¹¹¹In]Pr could be pretargeted in vivo to GPA33-expressing human colorectal cancer SW1222 xenografts with radioactive uptakes in the range of 13-17 %IA/g for tumor, and with liver showing modest radioactive uptake for [²²⁵Ac]Pr (~1.5 %IA/g) and kidney (~1.0 %IA/g) for [¹¹¹In]Pr. These activities in tumor and normal tissues resulted in T:NT with both haptens of ≥~12:1 at 24 h p.i. of tracers, consistent with previous studies in SW1222 tumor-bearing mice with GPA33 β-DOTA-PRIT (T:NT ≥~18:1 at 24 h p.i., with ~10 %IA/g for tumor) [19]. These tissue uptake ratios translate into high TI and provide a basis for potentially curative regimens for both α- and β-emitters.

The purpose of this study was to introduce a new DOTA-PRIT hapten for α-PRIT that allows us to obtain significant tumor responses, including CRs and cures, without toxicity. Furthermore, while we establish therapeutic efficacy without observing adverse effects, these initial studies provide benchmarks for further optimization of α-DOTA-PRIT, including: (1) improved tracer dosing with higher specific or molar activity preparations of [²²⁵Ac]Pr to balance tumor saturation with normal tissue uptake; (2) dosimetry studies to establish dose-response correlates and account for the complexity of the ²²⁵Ac-decay chain (i.e., in vivo fate of the recoiled daughter isotopes on α-emission), as well as the intra-cellular residence of [²²⁵Ac]Pr; (3) utilize protein engineering innovations to simplify dosing; and (4) utilize fractionated treatment regimens to potentially improve therapeutic outcome. We consider these important experiments to be outside the scope of the current manuscript.

Using DOTA-PRIT for tumor targeting of [²²⁵Ac]Pr in models of human colon cancer, breast cancer, or neuroblastoma, tested activities ranging from 37-296 kBq of ²²⁵Ac/mouse were well tolerated, while tumors were ablated. α-DOTA-PRIT therapy was not limited by acute or chronic radiotoxicity to normal organs. We demonstrated that GPA33 α-DOTA-PRIT was effective in SW1222 tumor-bearing mice, observing marginal but significant therapeutic effects (tumor growth control with prolonged survival; P<0.0001; Mantel-Cox test), with no detectable hematopoietic toxicity. Tumor response was likely limited by a combination of factors including the non-internalizing huA33 BsAb-GPA33 antibody-antigen complex [44] and low [²²⁵Ac]Pr specific activity, significantly impacting tumor localization of decay daughters and absolute tumor uptake of ²²⁵Ac, respectively. Furthermore, treatment of solid tumors with α-particle RIT, including α-DOTA-PRIT, may be theoretically limited by the potential mismatch between limited antibody penetration in tumor [45] and the short penetration depth of α-particles, leading to intratumoral absorbed dose heterogeneity.

Although not a requirement for efficacy, the application of internalizing mAb for improved α-RIT potency has been demonstrated [46], as there is a limited probability of α-particles originating on the cell surface to traverse a cell due to the high recoil energy of α-particle emission and daughter product release [47]. We show that using an internalizing HER2 BsAb for treatment of BT-474 tumor-bearing mice, we can achieve 7/19 (37%) CRs, including 10/19 (53%) with verified histologic cure at ~150 d post-treatment. This result was somewhat surprising, considering that we anticipated that the low molar activity of [²²⁵Ac]Pr would potentially impair responses as we observed for GPA33 α-DOTA-PRIT. We cautiously attribute this high level of efficacy to a combination of factors, including increased probability of exposure of tumor to α-particles due to increased internalization [48], as well as possibly higher radiosensitivity compared with SW1222 based on our previous β-DOTA-PRIT studies. We establish benchmarks for kidney toxicity, as remarkable tubulointerstitial features included minimal to mild multifocal cortical tubular degeneration and atrophy in 5/6 (83%) HER2 α-DOTA-PRIT (296 kBq)-treated animals. These lesions were interpreted as probably caused by the treatment, but they were not considered adverse, as they did not appear to significantly affect renal function or general health of the animals, based on the low percentage of the renal parenchyma affected (< 5%), normal serum CREA concentration and minimal elevation of BUN, and absence of clinical signs or change in body weight.

Also, we demonstrate in IMR-32 tumor-bearing mice that 100% of CRs could be achieved with a single pretargeted administered activity of 37 kBq, including 4/7 showing histologic cure at 141-241 d post-treatment. We hypothesize this remarkable efficacy to the relative radio-sensitivity of the model to [²²⁵Ac]Pr treatment, even though the hu3F8 BsAb-GD2 antibody-antigen complex is minimally internalizing [38, 49]. No treatment-related histopathologic changes were noted in 4/4 (100%) GD2 α-DOTA-PRIT (37 kBq)-treated animals.

In addition to therapy applications, the ability to readily image tumor with high contrast to normal tissue is significant for staging as well as dosimetry. The development of theranostic pairs for patient-specific dosimetry has been described as imperative for precision molecular radiotherapy (e.g., radiotherapy of prostate-specific membrane antigen using α- and β-emitters [50]). As a theranostic pair for ⁹⁰Y or ¹⁷⁷Lu β-DOTA-PRIT, ⁸⁶Y can also be used for positron emission tomography (PET) [19]. As a theranostic pair for [²²⁵Ac]Pr, ¹¹¹In is more convenient due to its considerably lower cost and availability (compared to ⁸⁶Y), as well as its acceptance in routine nuclear medicine SPECT imaging, which is still more widely available than PET. In addition, ¹¹¹In has a half-life of 2.8 d, a better match to the half-life of ²²⁵Ac (10 d) in comparison to ⁸⁶Y (14 h), for the purposes of dosimetry estimates. The use of ¹¹¹In as a surrogate for ²²⁵Ac was previously described in an antibody-oligonucleotide/radiolabeled oligonucleotide PRIT system by Mulvey, et al. [51]. We demonstrate that [¹¹¹In]Pr is a suitable SPECT imaging surrogate for [²²⁵Ac]Pr for dosimetry and treatment monitoring, with comparably high TI and low uptake in the key normal tissues, kidney, liver, and bone. Thus, as a theranostic radiohapten, [¹¹¹In]Pr will help establish optimized α-therapy regimens centered on quantitative dosimetry, emphasizing cures with minimal toxicity in target organs.

Conclusion

In summary, we have described a novel proteus-DOTA that can efficiently chelate ²²⁵Ac for use as a small radioligand for DOTA-PRIT. In addition, we have developed [¹¹¹In]Pr as a SPECT-imaging surrogate for [²²⁵Ac]Pr for dosimetry and treatment monitoring. Finally, we have established therapeutic activity of α-DOTA-PRIT in models of human colon cancer, breast cancer, or neuroblastoma. Furthermore, these anti-tumor effects were comparable to those achieved with β-DOTA-PRIT, although with much lower levels of administered [¹⁷⁷Lu]LuDOTA-Bn radioactivity (for GPA33: 55 MBq/mouse [19]; for HER2: 167 MBq/mouse [20]; for GD2: 33 MBq/mouse [17]), consistent with recently reported preclinical α-therapy studies [41] including α-PRIT [52, 53]. With pharmacodynamic control of radiotoxic non-tumor-bound [²²⁵Ac]Pr, DOTA-PRIT offers a meaningful improvement in the selectivity of α-therapy.

Abbreviations

PRIT: pretargeted radioimmunotherapy; TI: therapeutic index; RIT: radioimmunotherapy; BsAb: bispecific anti-tumor/anti-DOTA-hapten antibody; DOTA: 1,4,7,10-tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid; scFv: single-chain variable fragment; CA: clearing agent; MW: molecular weight; Pr: proteus-DOTA; SI: supplemental information; SPECT/CT: single-photon emission computed tomography/computed tomography; i.v.: intravenous; NSS: normal sterile isotonic saline solution; %IA/g: percent injected activity per gram; p.i.: post-injection; DO3A: three-arm DOTA radiometal-chelating agent; RP: reverse-phase; HPLC: high-pressure liquid chromatography; LC/MS: liquid-chromatography/mass spectrometry; NMR: nuclear magnetic resonance; RCY: radiochemical yield; RCP: radiochemical purity; EDTA: ethylenediaminetetraacetic acid; MTD: maximum tolerated dose; RBE: relative biologic effectiveness; LET: linear energy transfer; BLI: bioluminescent imaging; WBC: white blood cell; NE: neutrophils; LY: lymphocytes; MO: monocytes; EO: eosinophils; BA: basophils; RBC: red blood cell; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red cell distribution width; PLT: platelets; MPV: mean platelet volume; SD: standard deviation; %IA: percent injected activity; VOI: volume of interest; T:NT: tumor-to-organ activity ratios; IHC: immunohistochemistry; MS: median survival; CR: complete response; CBC: complete blood count; BUN: blood urea nitrogen; CREA: creatinine; PET: positron emission tomography.

Supplementary Material

Supplementary figures and tables.

Acknowledgements

We thank Dr. Tony Taldone and Dr. Sophie Poty for helpful discussions. We thank Ms. Leah Bassity and Mr. Garon Scott for editorial assistance. This study was supported in part by the Donna & Benjamin M. Rosen Chair (to S.M.L), Enid A. Haupt Chair (to N.K.C), The Center for Targeted Radioimmunotherapy and Theranostics, the Ludwig Center for Cancer Immunotherapy of MSKCC (to S.M.L), Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research (to S.M.L), and Experimental Therapeutics Center of MSKCC (to S.M.L). S.M.L was also supported in part by NIH grant P50-CA86438. This study also received support from NIH grant R01 CA233896 (PI: S.M.C). Technical services provided by the MSK Small-Animal Imaging Core Facility and Laboratory of Comparative Pathology were supported by Cancer Center Support Grant P30 CA008748. A Shared Resources Grant from the MSKCC Metastasis Research Center (to P.B.Z), which provided funding for the purchase of the NanoSPECT/CT, is gratefully acknowledged. Dr. Ouerfelli is supported by NCI grant R50 CA243895-01.

Competing Interests

N.K.C reports receiving commercial research grants from Y-mAbs Therapeutics, Inc. in 2015 and Abpro-Labs, Inc. in 2017, holding ownership interest/equity in Y-mAbs Therapeutics and in Abpro-Labs, and owning stock options in Eureka Therapeutics, Inc. N.K.C is the inventor and owner of issued patents licensed by MSK to Y-mAbs Therapeutics, Biotec Pharmacon, and Abpro Labs. These include US patents 6451995, 7507724, 7704973, 7740845, 7666424, 9315585, and multiple pending patents. N.K.C is a scientific advisory board member of Abpro Labs and Eureka Therapeutics. N.K.C, S.M.L, and S.M.C were named as one of the inventors in the following patent applications relating to GPA33: SK2014-074, SK2015-091, SK2017-079, SK2018-045, SK2014-116, SK2016-052, and SK2018-068 filed by MSK. S.M.L reports receiving commercial research grants from Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; holding ownership interest/equity in Elucida Oncology, Inc. and Y-mAbs Therapeutics, and holding stock in ImaginAb, Inc. S.M.L is the inventor and owner of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., Elucida Oncology, Inc., and Y-mAbs Therapeutics, Inc. S.M.L serves or has served as a consultant to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., and Janssen Pharmaceuticals, Inc. G.Y and O.O are listed as inventors and receive royalties from patents that were filed by MSK. O.O is an unpaid member of the scientific advisory board of Angiogenex and owns shares in Angiogenex. B.H.S and N.K.C are inventors on US Patent No. 62/502,151. D.A.S is a consultant to, on the board of, and/or has equity in: PGNX, SLS, KLUS, IOVA, PFE, ATNM, Oncopep and Eureka Therapeutics. MSK has filed for patent protection on behalf of D.A.S for technology discussed in this paper. All other authors have no competing interests.

References

1. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 2012;503:255-68

2. Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol. 2011;13:215-21

3. Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347-60

4. Hapuarachchige S, Huang CT, Donnelly MC, Barinka C, Lupold SE, Pomper MG. et al. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. Mol Pharm. 2020;17:98-108

5. Verhoeven M, Seimbille Y, Dalm SU. Therapeutic Applications of Pretargeting. Pharmaceutics. 2019 11

6. Liu G. A Revisit to the Pretargeting Concept-A Target Conversion. Front Pharmacol. 2018;9:1476

7. Strebl MG, Yang J, Isaacs L, Hooker JM. Adamantane/Cucurbituril: A Potential Pretargeted Imaging Strategy in Immuno-PET. Mol Imaging. 2018;17:1536012118799838

8. Altai M, Membreno R, Cook B, Tolmachev V, Zeglis BM. Pretargeted Imaging and Therapy. J Nucl Med. 2017;58:1553-9

9. Frampas E, Rousseau C, Bodet-Milin C, Barbet J, Chatal JF, Kraeber-Bodere F. Improvement of radioimmunotherapy using pretargeting. Front Oncol. 2013;3:159

10. Goldenberg DM, Chang CH, Rossi EA. et al. Pretargeted molecular imaging and radioimmunotherapy. Theranostics. 2012;2:523-40

11. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003;44:400-11

12. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV. et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel. 2010;23:221-8

13. Corneillie TM, Fisher AJ, Meares CF. Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system. J Am Chem Soc. 2003;125:15039-48

14. Corneillie TM, Whetstone PA, Fisher AJ, Meares CF. A rare earth-DOTA-binding antibody: probe properties and binding affinity across the lanthanide series. J Am Chem Soc. 2003;125:3436-7

15. Orcutt KD, Slusarczyk AL, Cieslewicz M, Ruiz-Yi B, Bhushan KR, Frangioni JV. et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol. 2011;38:223-33

16. Orcutt KD, Rhoden JJ, Ruiz-Yi B, Frangioni JV, Wittrup KD. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther. 2012;11:1365-72

17. Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Molecular cancer therapeutics. 2014;13:1803-12

18. Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB. et al. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2017;58:1735-42

19. Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S. et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity (8)(6)Y- or (1)(7)(7)Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging. 2016;43:925-37

20. Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK. et al. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics. 2018;8:5106-25

21. Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH. et al. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. Cancer Res. 2016;76:6669-79

22. Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK. et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. 2018;131:611-20

23. McDevitt MR, Sgouros G, Sofou S. Targeted and Nontargeted alpha-Particle Therapies. Annual review of biomedical engineering. 2018;20:73-93

24. Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. alpha-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. J Nucl Med. 2018;59:878-84

25. Pandit-Taskar N. Targeted Radioimmunotherapy and Theranostics with Alpha Emitters. J Med Imaging Radiat Sci. 2019;50:S41-S4

26. Tafreshi NK, Doligalski ML, Tichacek CJ, Pandya DN, Budzevich MM, El-Haddad G. et al. Development of Targeted Alpha Particle Therapy for Solid Tumors. Molecules. 2019 24

27. Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting alpha-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102-18

28. Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. Journal of the American Society of Nephrology: JASN. 2005;16:2677-89

29. Nedrow JR, Josefsson A, Park S, Back T, Hobbs RF, Brayton C. et al. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI research. 2017;7:57

30. Cheal SM, Patel M, Yang G, Veach DR, Xu H, Guo HF. et al. A N-acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjugate chemistry. 2019

31. McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot. 2002;57:841-7

32. Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev. 2020;120:3787-851

33. Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. alpha-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2. J Nucl Med. 2018;59:1020-7

34. Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60:1371-82

35. McDevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of Shiva. Cell Death Differ. 2002;9:593-4

36. Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C. et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer research. 2009;69:8941-8

37. Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM. et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Physics in medicine and biology. 2011;56:721-33

38. Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK. et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res. 2004;10:6985-92

39. Essler M, Gartner FC, Neff F, Blechert B, Senekowitsch-Schmidtke R, Bruchertseifer F. et al. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging. 2012;39:602-12

40. Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R. et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res. 2008;14:3555-61

41. Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I. et al. Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In vivo Tumor Visualization. Theranostics. 2016;6:698-709

42. Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S. et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15-29

43. Green DJ, Press OW. Whither Radioimmunotherapy: To Be or Not To Be? Cancer Res. 2017;77:2191-6

44. Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ. et al. A33 antigen displays persistent surface expression. Cancer Immunol Immunother. 2008;57:1017-27

45. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007;48:995-9

46. Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P. et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One. 2013;8:e69613

47. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K. et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40:166-76

48. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK. et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-40

49. Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J. et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med. 2004;45:867-77

50. Kulkarni HR, Singh A, Langbein T, Schuchardt C, Mueller D, Zhang J. et al. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. The British journal of radiology. 2018: 20180308.

51. Mulvey JJ, Villa CH, McDevitt MR, Escorcia FE, Casey E, Scheinberg DA. Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nature nanotechnology. 2013;8:763-71

52. Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A. et al. alpha- Versus beta-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts. J Nucl Med. 2017;58:926-33

53. Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A. et al. Leveraging Bioorthogonal Click Chemistry to Improve (225)Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019;25:868-80

Author contact

Corresponding author: Steven M. Larson, MD, FACNM, FACR, 415 East 68th Street, Z-2064, New York, NY 10065. Tel: 646-888-2212; Fax: 212-717-3263; E-mail: larsonsorg; ORCID ID: orcid.org/0000-0002-6111-7507.

Received 2020-5-28
Accepted 2020-7-29
Published 2020-9-14

Citation styles

©2024 Ivyspring International Publisher. Terms of use